Compounds > morolic acid
Page last updated: 2024-09-27

morolic acid

Description

morolic acid: from Pistacia terebinthus galls; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
PistaciagenusA plant genus in the ANACARDIACEAE family known for species that produce pistachio nuts (Pistacia vera) and GUM MASTIC (Pistacia lentiscus). Several of the species have the common name Pistachio.[MeSH]AnacardiaceaeThe sumac plant family in the order Sapindales, subclass Rosidae, class Magnoliopsida. They are tropical and subtropical trees, shrubs, and woody vines that have resin ducts in the bark. The sap of many of the species is irritating to the skin.[MeSH]
Pistacia terebinthusspecies[no description available]AnacardiaceaeThe sumac plant family in the order Sapindales, subclass Rosidae, class Magnoliopsida. They are tropical and subtropical trees, shrubs, and woody vines that have resin ducts in the bark. The sap of many of the species is irritating to the skin.[MeSH]

Cross-References

ID SourceID
PubMed CID489944
CHEMBL ID463665
SCHEMBL ID3678795
MeSH IDM0430857

Synonyms (11)

Synonym
morolic acid
(4as,6ar,6ar,6br,8ar,10s,12ar,14as)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-3,4,5,6,6a,7,8,8a,10,11,12,13,14,14a-tetradecahydropicene-4a-carboxylic acid
3.beta.-hydroxy-3-deoxymoronic acid
(4as,6ar,6br,8ar,10s,12ar,12br,14as)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14,14a-octadecahydro-2h-picene-4a-carboxylic acid
CHEMBL463665 ,
bdbm50391854
SCHEMBL3678795
559-68-2
olean-18-en-28-oic acid,3-hydroxy-,(3b)-
DTXSID001317975
AKOS040762070

Research Excerpts

Overview

ExcerptReference
"Morolic acid is a plant-derived triterpenoid that possesses pharmacological properties such as cytotoxicity, as well as anti-HIV, anti-HSV, anti-inflammatory, and antidiabetic effects. "( Fukushima, EO; Muranaka, T; Robertlee, J; Seki, H; Srisawat, P; Yasumoto, S, 2020)

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Receptor-type tyrosine-protein phosphatase FHomo sapiens (human)IC50 (µMol)35.90001.30002.66604.2300AID687543
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)9.10000.00053.49849.7600AID687539
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)Ki7.10000.19004.83279.6000AID687545
Low molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)IC50 (µMol)22.00002.86009.633617.2000AID687540; AID687541
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (34)

Processvia Protein(s)Taxonomy
cell adhesionReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
cell surface receptor protein tyrosine phosphatase signaling pathwayReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
cell migrationReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
neuron projection regenerationReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
peptidyl-tyrosine dephosphorylationReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
regulation of axon regenerationReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
synaptic membrane adhesionReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
negative regulation of receptor bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
transmembrane receptor protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
heparin bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
chondroitin sulfate proteoglycan bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
protein-containing complex bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
cell adhesion molecule bindingReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
acid phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
protein tyrosine phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
protein bindingLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
plasma membraneReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
neuron projectionReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
neuronal cell bodyReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
extracellular exosomeReceptor-type tyrosine-protein phosphatase FHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
cytosolLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
cytoplasmic side of plasma membraneLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
sarcolemmaLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
extracellular exosomeLow molecular weight phosphotyrosine protein phosphataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID687541Inhibition of human recombinant LMW-PTP2 expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate after 1 hr2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID687539Inhibition of human recombinant PTP-1B expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate after 1 hr2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID687542Inhibition of yeast LMW-PTP1 expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate after 1 hr2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID687538Inhibition of human recombinant PTP-1B expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate at 10 to 50 uM after 1 hr2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID357961Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA2001Journal of natural products, Oct, Volume: 64, Issue:10
Anti-AIDS agents. 48.(1) Anti-HIV activity of moronic acid derivatives and the new melliferone-related triterpenoid isolated from Brazilian propolis.
AID687540Inhibition of human recombinant LMW-PTP1 expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate after 1 hr2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID687534Antidiabetic activity in STZ-nicotinamide diabetic Wistar rat T2DM model assessed as decrease in blood glucose level at 50 mg/kg, po after 3 hrs by enzymatic glucose oxidase method relative to control2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID687545Non-competitive inhibition of human recombinant PTP-1B expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID357960Cytotoxicity against human H9 cells2001Journal of natural products, Oct, Volume: 64, Issue:10
Anti-AIDS agents. 48.(1) Anti-HIV activity of moronic acid derivatives and the new melliferone-related triterpenoid isolated from Brazilian propolis.
AID687535Antidiabetic activity in STZ-nicotinamide diabetic Wistar rat T2DM model assessed as decrease in blood glucose level at 50 mg/kg, po after 5 hrs by enzymatic glucose oxidase method relative to control2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID687533Antidiabetic activity in STZ-nicotinamide diabetic Wistar rat T2DM model assessed as decrease in blood glucose level at 50 mg/kg, po after 1 hr by enzymatic glucose oxidase method relative to control2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID687543Inhibition of human recombinant LAR expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate after 1 hr2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID687536Antidiabetic activity in STZ-nicotinamide diabetic Wistar rat T2DM model assessed as decrease in blood glucose level at 50 mg/kg, po after 7 hrs by enzymatic glucose oxidase method relative to control2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Antidiabetic activity of some pentacyclic acid triterpenoids, role of PTP-1B: in vitro, in silico, and in vivo approaches.
AID357962Therapeutic index, ratio of IC50 for human H9 cells to EC50 of HIV1 3B2001Journal of natural products, Oct, Volume: 64, Issue:10
Anti-AIDS agents. 48.(1) Anti-HIV activity of moronic acid derivatives and the new melliferone-related triterpenoid isolated from Brazilian propolis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (36.36)29.6817
2010's5 (45.45)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
vanillin[no description available]medium10benzaldehydes;
monomethoxybenzene;
phenols		anti-inflammatory agent;
anticonvulsant;
antioxidant;
flavouring agent;
plant metabolite
zidovudine[no description available]medium10azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
betulonic acid[no description available]medium10triterpenoidanticoronaviral agent
moronic acid[no description available]medium30pentacyclic triterpenoidanti-HIV agent;
anti-HSV-1 agent;
metabolite
glyburide[no description available]medium10monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
oleanolic acid[no description available]medium40hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
ursolic acid[no description available]medium10hydroxy monocarboxylic acid;
pentacyclic triterpenoid		geroprotector;
plant metabolite
methyl gallate[no description available]medium10gallate esteranti-inflammatory agent;
antioxidant;
plant metabolite
ethyl gallate[no description available]medium10gallate esterplant metabolite
gallic acid[no description available]medium10trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
gamma-sitosterol[no description available]medium103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
phytosterols		marine metabolite;
plant metabolite
cytellin[no description available]medium10
phytosterols[no description available]medium10
1-triacontanol[no description available]medium10fatty alcohol 30:0;
ultra-long-chain primary fatty alcohol
acetone[no description available]medium10ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent
betulinic acid[no description available]medium20hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
gamma-linolenic acid[no description available]medium20linolenic acid;
omega-6 fatty acid		human metabolite;
mouse metabolite;
plant metabolite
masticadienonic acid[no description available]medium10triterpenoid
tetradecanoylphorbol acetate[no description available]medium10acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
leukotriene b4[no description available]medium10dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid		human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent
calcimycin[no description available]medium10benzoxazole
cyproheptadine[no description available]medium10piperidines;
tertiary amine		anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist
masticadienolic acid[no description available]medium10
ConditionIndicatedRelationship StrengthStudiesTrials
Alloxan Diabetes0low20
Autoimmune Diabetes0low10
Diabetes Mellitus, Brittle0low10
Diabetes Mellitus, Experimental0low20
Diabetes Mellitus, Insulin-Dependent0low10
Diabetes Mellitus, Insulin-Dependent, 10low10
Diabetes Mellitus, Juvenile-Onset0low10
Diabetes Mellitus, Ketosis-Prone0low10
Diabetes Mellitus, Sudden-Onset0low10
Diabetes Mellitus, Type 10low10
Diabetes Mellitus, Type I0low10
Diabetes, Autoimmune0low10
Experimental Diabetes Mellitus0low20
IDDM0low10
Inflammation0low10
Innate Inflammatory Response0low10
Insulin-Dependent Diabetes Mellitus 10low10
Juvenile-Onset Diabetes0low10
Streptozocin Diabetes0low20
Streptozotocin Diabetes0low20
Type 1 Diabetes0low10
Type 1 Diabetes Mellitus0low10

Research Highlights

Natural Sources (1)

ArticleYear
Morolic Acid 3-
Molecules (Basel, Switzerland), Dec-13, Volume: 25, Issue: 24		2020
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]